Compared with combination therapy with alisertib and anti-IgG, combination therapy with alisertib and anti–B7-H3 mAbs significantly increased the abundance of total CD3+ T cells, tumor-infiltrating CD8+ T cells, perforin+ cells and granzyme B+ cells but not total CD4+ T cells (Figure 9, A and B). This evidence concerns the gene CD4 and neoplasm.